HISTAMINE, LEUKOTRIENE-C4 AND INTERLEUKIN-2 INCREASE ANTIBODY UPTAKE INTO A HUMAN CARCINOMA XENOGRAFT MODEL

被引:25
作者
HENNIGAN, TW [1 ]
BEGENT, RHJ [1 ]
ALLENMERSH, TG [1 ]
机构
[1] ROYAL FREE HOSP,SCH MED,DEPT CLIN ONCOL,CANC RES CAMPAIGN CLIN RES LABS,LONDON NW3 2PF,ENGLAND
关键词
D O I
10.1038/bjc.1991.416
中图分类号
R73 [肿瘤学];
学科分类号
100214 ;
摘要
Systemically administered radiolabelled anti-tumor antibody is ineffective in treating the majority of patients with liver metastasis from colorectal carcinoma. We have assessed whether agents which increase capillary permeability can increase tumour uptake of antibody isotope conjugate. We developed a xenograft model of colorectal carcinoma using an antibody directed against carcinoembryonic antigen (CEA). Tumours were grown subcutaneously in the hind limbs of athymic rats to derive their circulation from the femoral artery. Cannulae were placed in the common iliac artery and iliolumbar vein. Antibody was delivered systemically, regionally and regionally with histamine, leukotriene C4 and interleukin-2. Regionally administered anti-CEA antibody resulted in a significantly greater (P = 0.004) tumour to normal tissue ratio (1.66, s.d. = 0.68) compared to systemically administered antibody (1.25, s.d. = 0.73). The addition of vasoactive drugs produced an approximately 3-fold increase with an increase to a mean tumour:liver ratio of 3.24 (s.d. = 1.39) for histamine (P < 0.001 compared to systemic delivery), 3.21 (s.d. = 1.13, P < 0.001) for leukotriene C4 and 3.80 (s.d. = 1.53, P < 0.001) for interleukin-2. The addition of histamine significantly (P = 0.004) increased the mean tumour to liver ratio (1.73, s.d. = 0.44) of non-specific antibody uptake compared with either systemic (1.12, s.d. = 0.24) or regional delivery (1.25, s.d. = 0.54) of non-specific antibody alone. Increasing tumour capillary permeability can produce a significant clinically useful increase in tumour uptake of antibody-isotope conjugate.
引用
收藏
页码:872 / 874
页数:3
相关论文
共 15 条
[1]   RENAL AND SYSTEMIC HEMODYNAMIC-RESPONSES TO INTRAVENOUS-INFUSION OF LEUKOTRIENE-C4 IN THE RAT [J].
BADR, KF ;
BAYLIS, C ;
PFEFFER, JM ;
PFEFFER, MA ;
SOBERMAN, RJ ;
LEWIS, RA ;
AUSTEN, KF ;
COREY, EJ ;
BRENNER, BM .
CIRCULATION RESEARCH, 1984, 54 (05) :492-499
[2]   ANTIBODY DISTRIBUTION AND DOSIMETRY IN PATIENTS RECEIVING RADIOLABELED ANTIBODY THERAPY FOR COLORECTAL-CANCER [J].
BEGENT, RHJ ;
LEDERMANN, JA ;
GREEN, AJ ;
BAGSHAWE, KD ;
RIGGS, SJ ;
SEARLE, F ;
KEEP, PA ;
ADAM, T ;
DALE, RG ;
GLASER, MG .
BRITISH JOURNAL OF CANCER, 1989, 60 (03) :406-412
[3]  
DOUGLAS W, 1980, PHARM BASIS THERAPEU
[4]   RADIOIMMUNOTHERAPY OF CANCER - CLINICAL-STUDIES AND LIMITING FACTORS [J].
DYKES, PW ;
BRADWELL, AR ;
CHAPMAN, CE ;
VAUGHAN, ATM .
CANCER TREATMENT REVIEWS, 1987, 14 (02) :87-106
[5]  
FROLICH JC, 1987, BRIT J PHARMACOL, V92, P311
[6]  
GOETZ A, 1987, ADV PROSTAGLANDIN TH, V17
[7]   PREPARATION OF 131I-LABELLED HUMAN GROWTH HORMONE OF HIGH SPECIFIC RADIOACTIVITY [J].
GREENWOOD, FC ;
HUNTER, WM .
BIOCHEMICAL JOURNAL, 1963, 89 (01) :114-&
[8]  
HAPLERN SE, 1986, J NUCL MED, V25, P112
[9]  
ROSENSTEIN M, 1986, J IMMUNOL, V137, P1735
[10]  
SANDS H, 1986, CANCER IMMUNOL IMMUN, V22, P169